| Expression pattern: |
UP |
| Associated gene: |
mRNA/lncRNA network, miRNA target genes |
| Associated microRNA: |
hsa-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-181d-5p, hsa-miR-338-3p, hsa-miR-526b-5p |
| Biological function: |
circ-ANAPC7 is significantly upregulated in AML, may act as an oncogenic circRNA, and is proposed as a promising biomarker and potential drug target for AML. |
| Molecular mechanism: |
Predicted ceRNA mechanism: circ-ANAPC7 may act as a sponge for the miR-181 family and regulate miRNA-associated target genes in AML. |
| Biological pathway or process: |
ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
RNase R Treatment; Microarray; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
circ-ANAPC7 is proposed as a promising biomarker for AML and may be used for AML diagnosis or as a novel drug target, but the authors state that clinical significance was not elucidated due to short follow-up. |
| Description: |
circ-ANAPC7/hsa_circRNA_101141, derived from the ANAPC7 gene locus, was significantly upregulated in AML bone marrow samples and validated by qRT-PCR. The study suggests that circ-ANAPC7 may contribute to AML pathogenesis as an oncogenic circRNA by acting as a predicted sponge for the miR-181 family and engaging cancer-related pathways. It is proposed as a promising AML biomarker and potential therapeutic target, although its clinical significance was not established due to limited follow-up. |
| Confidence score: |
0.585 |